RCUS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Arcus Biosciences Inc (RCUS) presents a good buying opportunity for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The stock has strong hedge fund interest, positive analyst sentiment, and potential catalysts in its pipeline. Despite some negative news and financial losses, the company's revenue growth and promising drug developments make it a solid long-term investment.
The stock shows bullish momentum with MACD above 0 and positively contracting, RSI in the neutral zone at 59.708, and bullish moving averages (SMA_5 > SMA_20 > SMA_200). Key resistance levels are at $27.502 and $29.501, while support levels are at $21.031 and $19.032.
Hedge funds are significantly increasing their positions in the stock (186.42% increase in buying).
Analysts maintain a positive outlook with multiple 'Buy' and 'Outperform' ratings and price targets ranging from $32 to $
Potential positive outcomes for casdatifan in Phase 3 trials, which could make it the only marketed HIF2alpha inhibitor in its indication.
Revenue growth of 26.92% YoY in Q4 2025.
Discontinuation of STAR-121 and Phase 2 Edge-Lung studies, which could indicate challenges in parts of the pipeline.
Net income remains negative at -$106 million, and EPS dropped by -13.59% YoY in Q4 2025.
In Q4 2025, revenue increased by 26.92% YoY to $33 million, indicating strong growth. However, the company reported a net loss of -$106 million, though this was an improvement of 12.77% YoY. EPS dropped to -0.89, down -13.59% YoY, while gross margin remained at 100%.
Analysts maintain a positive outlook with recent price targets ranging from $32 to $49. H.C. Wainwright, Leerink, Wedbush, and Citi have reiterated 'Buy' or 'Outperform' ratings, citing strong pipeline potential and business development opportunities. However, Wells Fargo downgraded the stock to 'Equal Weight' with a $23 price target due to potential data readout headwinds.
